RE:RE:Phone call Mrs. LeahIf you can read this LEAH GIBSON...this is such a crappy company! Ive been holding onto this crappy company for over 12 year and literally have not seen any price appreication. You have literally screwed us over...again and again and again. Do you not care about your long-term holder who pays your paycheck? Why are you biting the hand that feeds you? Soon, that food will go away and you will be left homeless in the street.
Next, dont call the broader market a biotech bubble when this company did not even run up like the other biotech company...if you cant even get your price up, please dont try to speculate on the market. It just makes your either sound ignorant or envious of the run-up in other sucessful biotech companies.
Lastly, do your JOB better. For a Senior Director of PR, you guys are terrible. Your PR team is weak at least. It takes you forever to get anything out. Your marketing site, material, presentation is elementary at best. My teenager can do a better job building you a website and probably at a fraction of a time.
palinc2000 wrote: I agree with her comment that things have changed for the better since the last 10 months(since the new CEO) BUT this did not translate into more PERCEIVED value by the market
canadapiet wrote: Me disappointed (again)!!!!
The call:
- she reads the MB because; i have e- mailed her the questions Wino was mentioning and she said she read them and suggested to eventually answer them line by line........
-regarding the Nasdaq listing and doing a capital increase by that time: "they didn't need the money then"......(OMG.....)
- they can not disclose who are the "buyers"
-they looked at the market now and decided they needed the money now because the markets were willing to deal with it now (we are in a biotech bubble she said, and now was the time to do the increase) OMG
- they could have raised more (OMG)
- Cannacord for the US and NBF for Canada
- they had other talks with banks but that was the deal they wanted ??????!!!!!(OMG)
- doing a deal with a BP is giving up on a big chunk of future profits
- tesamorelin is from the company and they want to hold it that way for now to shine later in the Nash market
- oncology to early for a good deal ????? (velosbio was preclinical and bought for 1,2 billion.......)
- they did it to streghten the balance sheet so they had the certainty to go forward and so wouldn't be blocked if the markets crashed
- the type of investors: before the deal, TH is owned by retail and individual investors, and they wanted a more diversed shareholder base (institutions)
- r&d and money : oncology can go quickly and they must be prepared fot the next fase, but they are not expecting intermediate results(?????), so that's for next year......
- fda accaptance: end of Q3 start for Nash (but still have a conversation with fda regarding the protocol, endpoints etc )
- strong financial position for now, but to early to speculate on any further capital increase
- why invest in the company now : no value for any molecule + good financial position + existing products selling better
- old shareholders : they are working to have a better relation, they understand the frustation, they are doing things better now the last 10 months, they will be recognised in the us and will have a better exposure over there, there is substantial change for the better,they have to execute and there is no room anymore for failure ..........OMG
We laughed at the end because mentioning "what's another year" if you are waiting allready such a long time and by the way "they are all shareholders and they also want the price to go up"........
Good luck all